{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-002697","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.000138+00:00","generated_at":"2026-05-16T10:54:13.394458+00:00","sec_items":["8.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioXcel names Mark Pavao Interim CCO; plans sNDA for IGALMI at-home use","bullets":["Mark Pavao appointed Interim Chief Commercial Officer to support potential IGALMI at-home launch.","Company plans to submit supplemental NDA this month for FDA approval of IGALMI for at-home use.","IGALMI targets acute agitation in bipolar disorders or schizophrenia; at-home expansion is key strategic move."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-002697","json":"https://secwatch.observer/filing/0001104659-26-002697.json","markdown":"https://secwatch.observer/filing/0001104659-26-002697.md","text":"https://secwatch.observer/filing/0001104659-26-002697.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926002697/0001104659-26-002697-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926002697/tm262900d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:54:13.394458+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}